Bristol-Myers: progress in pulmonary fibrosis
(CercleFinance.com) - Bristol Myers Squibb yesterday announced results from a Phase 2 study evaluating BMS-986278, a potential first-in-class oral lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis.
The study showed that twice-daily administration of 60 mg of BMS-986278 for 26 weeks reduced the rate of decline in percentage predicted forced vital capacity (ppFVC) by 62% compared to placebo.
BMS-986278 was well tolerated, with adverse event and discontinuation rates comparable to placebo.
Pulmonary fibrosis is a devastating, life-threatening disease with daily symptoms of coughing, difficult breathing and extreme fatigue.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The study showed that twice-daily administration of 60 mg of BMS-986278 for 26 weeks reduced the rate of decline in percentage predicted forced vital capacity (ppFVC) by 62% compared to placebo.
BMS-986278 was well tolerated, with adverse event and discontinuation rates comparable to placebo.
Pulmonary fibrosis is a devastating, life-threatening disease with daily symptoms of coughing, difficult breathing and extreme fatigue.
Copyright (c) 2023 CercleFinance.com. All rights reserved.